Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II | Zendy

Elizabeth R. Volkmann | Zendy; Donald P. Tashkin | Zendy; MyungShin Sim | Zendy; Ning Li | Zendy; Dinesh Khanna | Zendy; Michael D. Roth | Zendy; Philip J. Clements | Zendy; AnnaMaria HoffmannVold | Zendy; Daniel E. Furst | Zendy; Grace Kim | Zendy; Jonathan Goldin | Zendy; Robert M. Elashoff | Zendy

Open Access

Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II

Author(s) -

Elizabeth R. Volkmann,

Donald P. Tashkin,

MyungShin Sim,

Ning Li,

Dinesh Khanna,

Michael D. Roth,

Philip J. Clements,

AnnaMaria HoffmannVold,

Daniel E. Furst,

Grace Kim,

Jonathan Goldin,

Robert M. Elashoff

Publication year - 2019

Publication title -

the journal of rheumatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.577

H-Index - 178

eISSN - 1499-2752

pISSN - 0315-162X

DOI - 10.3899/jrheum.180441

Subject(s) - dlco , medicine , vital capacity , interstitial lung disease , placebo , scleroderma (fungus) , pulmonary function testing , cyclophosphamide , gastroenterology , diffusing capacity , lung , restrictive lung disease , spirometry , clinical endpoint , surgery , randomized controlled trial , lung function , chemotherapy , pathology , asthma , alternative medicine , inoculation

To compare safety and efficacy outcomes between the cyclophosphamide (CYC) arms of Scleroderma Lung Study (SLS) I and II.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research